Davide Capodanno Shares FITTER Trial: Evolocumab Shows No Added Short-Term Benefit in Acute Coronary Syndrome
Davide Capodanno, professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”In the double-blind, randomized FITTER trial, 150 patients with acute coronary syndrome and relevant non-culprit lesions received evolocumab or placebo for 12 weeks in addition to high-intensity statin therapy.
PCSK9 inhibition did not produce additional short-term improvements in plaque lipid content, plaque volume, or coronary physiology.”
Read the full article here.
Find the editorial here.
Article: Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial
Authors: Frans B. Mensink, Jonathan Los, Mohamed M. Reda Morsy, Rohit M. Oemrawsingh, Clemens von Birgelen, Alexander J.J. Ijsselmuiden, Martijn Meuwissen, Jin M. Cheng, Diederik F. van Wijk, Pieter C. Smits, Valeria Paradies, Dirk J. van Wijk, Himanshu Rai, Tim J.F. ten Cate, Cyril Camaro, Peter Damman, Lokien X. van Nunen1, Aukelien C. Dimitriu-Leen, Marleen H. van Wely, Aysun Cetinyurek-Yavuz, Robert A. Byrne, Niels van Royen, Robert-Jan M. van Geuns
Stay informed on all science in Hematology with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25